FLUOR-OP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).
Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.
| Metabolism | Fluorometholone is metabolized primarily in the liver via CYP3A4-mediated hydroxylation. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | Approximately 10-20% bound to plasma proteins, primarily albumin; low binding reduces risk of drug interactions. |
| Volume of Distribution | 0.15-0.25 L/kg, suggesting distribution primarily into extracellular fluid; low Vd reflects limited tissue penetration. |
| Bioavailability | Topical ophthalmic: Systemic bioavailability is <1% after ocular administration; topical dermatologic: Minimal systemic absorption (<5%) through intact skin. |
| Onset of Action | Ophthalmic (topical): 30-60 minutes for peak intraocular pressure reduction; topical dermatologic: 24-48 hours for antiviral effect; systemic absorption negligible with topical use. |
| Duration of Action | Ophthalmic: Duration of intraocular pressure reduction is 6-12 hours following instillation; requires multiple daily dosing (e.g., 3-4 times daily). For dermatologic use, antiviral effect persists with continued application. |
| Molecular Weight | 130.08 |
2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required for topical ophthalmic use; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for topical ophthalmic use; minimal systemic absorption. |
| Pediatric use | Children ≥2 years: same as adult dosing; safety and efficacy in children <2 years not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing with monitoring for ocular adverse effects. |
| 1st trimester | Fluorouracil is teratogenic in animals; contraindicated in pregnancy. Avoid use in first trimester unless clearly necessary. |
| 2nd trimester | Contraindicated; may cause fetal harm based on animal data. |
| 3rd trimester | Contraindicated; potential for fetal toxicity and adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).
| Placental transfer | Fluorouracil crosses the placenta; evidence from animal studies shows rapid transfer and accumulation in fetal tissues. |
| Breastfeeding | Fluorouracil is excreted into breast milk; potential for serious adverse reactions in nursing infants. Discontinue nursing or the drug, considering importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
Corticosteroids may increase intraocular pressure (IOP) in susceptible individuals, leading to glaucoma and optic nerve damage. Long-term use may suppress host immune responses and increase risk of secondary ocular infections. Prolonged use may also cause cataract formation.
| Serious Effects |
PregnancyBreastfeedingPatients with known hypersensitivity to fluorouracilSevere bone marrow depressionSevere infectionMajor surgery within past 4 weeksDihydropyrimidine dehydrogenase (DPD) deficiency
| Precautions | Monitor intraocular pressure regularly if used for 10 days or longer. Use with caution in patients with glaucoma, corneal thinning, or history of herpes simplex keratitis. Prolonged use may lead to fungal superinfection. Not for injection or oral use. |
| Food/Dietary | No clinically significant food interactions. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. Fluorouracil is teratogenic in animals; fetal malformations (cleft palate, skeletal defects) reported. Risk of fetal harm outweighs any potential benefit. Use effective contraception during treatment. |
| Fetal Monitoring | Pregnancy test before initiation. Monitor for signs of myelosuppression (CBC with differential weekly), mucositis, diarrhea, and hand-foot syndrome. Hepatic and renal function tests periodically. Fetal ultrasound if inadvertent exposure occurs. |
| Fertility Effects | Potential for impaired fertility in both males and females. Oligospermia, azoospermia, and amenorrhea reported. Effects may be transient or permanent depending on duration and dose. |
| Clinical Pearls | Apply a thin ribbon of ointment to the lower conjunctival fornix. Avoid contact with soft contact lenses. May cause transient stinging or blurring. Monitor for corneal epithelial toxicity with prolonged use. Use with caution in patients with corneal epithelial defects or stromal thinning. Discard after 30 days of opening. |
| Patient Advice | Wash hands before and after application. · Do not touch the tube tip to any surface. · Apply the prescribed amount without touching the eye. · Wait at least 5 minutes between different eye drops. · Do not wear soft contact lenses during treatment. · Report any eye pain, vision changes, or worsening redness. · Store at room temperature, away from moisture and heat. |